Assessment of health related quality of life (QOL) has become an important endpoint in many clinical trials of cancer therapy. Most of these studies entail multiple QOL scales that are assessed repeatedly over time. As a result, the problem of multiple comparisons is a primary analytic challenge wit
Endpoints in cancer clinical trials: is there a need for measuring quality of life?
β Scribed by Ronald Feld
- Publisher
- Springer-Verlag
- Year
- 1995
- Tongue
- English
- Weight
- 456 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0941-4355
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of stud
Measurement of quality of life (QOL) in cancer clinical trials has increased in recent years as more groups realize the importance of such endpoints. A key problem has been missing data. Some QOL data may unavoidably be missing, as for example when patients are too ill to complete forms. Other impor
Assessment of health related quality of life has become an important endpoint in many cancer clinical trials. Because the participants of these trials often experience disease and treatment related morbidity and mortality, non-random missing assessments are inevitable. Examples are presented from se